A
Agilent Technologies
$126.49
▼ 0.4%Updated Today 7:15 PM ET
▲ Up 10.0% over the last 12 months
Market Cap
$35.89B
P/E
25.67x
Forward P/E (est.)
20.97x
ROE
20.8%
Revenue Growth
9.1%
EPS Growth
22.4%
Profit Margin
19.6%
FCF Yield
4.0%
Debt / Equity
0.5x
ROIC
11.0%
Interest Coverage
13.21x
Current Ratio
2.1x
Dividend Yield
0.8%
Implied Growth (rev. DCF)
5.6%
Rating Score
62/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what A's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. A trades near $126.49, around its 50-day average ($120.94) and 200-day average ($130.43). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 29 it is oversold — selling has been heavy and a bounce is possible.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. A's is $4.08 (~3.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month A found buyers near $108.35 (support) and sellers near $141.09 (resistance); its 52-week range is $108.35–$160.27. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Agilent Technologies (A) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $35.89B.
In its latest reported year it generated about $6.95B in revenue and $1.30B in net profit.
Our model rates A Favorable (62/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
2.4%
Revenue moved from $6.32B in 2021 to $6.95B in 2025, a 2.4% compound annual growth rate. The most recent year grew a steady 9.1% year over year. Slower, mature growth is common for established businesses.
Gross Margin
52.9%
Operating Margin
21.3%
Net Margin
18.8%
ROE
20.8%
Agilent Technologies keeps about 19.6% of each sales dollar as net profit, with a 52.9% gross margin and 21.3% operating margin. Return on equity is 20.8% and return on invested capital about 11.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$3.05B
Net Debt
$1.24B
Net Debt / EBITDA
0.84x
Debt / Equity
0.5x
Leverage: debt-to-equity is 0.5x, and operating profit covers interest about 13.2x, with a current ratio of 2.1x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $3.05B of total debt against $1.81B of cash.
Operating CF
$1.56B
Free Cash Flow
$1.15B
FCF Margin
16.6%
In the latest year Agilent Technologies produced about $1.56B of operating cash flow and $1.15B of free cash flow after capital spending. That is a free-cash-flow yield of about 4.0% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
25.67x
P/S
5.28x
P/B
6.09x
EV / EBITDA
21.22x
A trades at 25.7x trailing earnings (about 21.0x on estimated forward earnings), 5.3x sales, and 6.1x book value. Reverse-engineering today's price implies the market expects roughly 5.6% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How A stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), A ranks #15 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (25.7x P/E vs. 25.4x median) with a higher return on equity (20.8% vs. 14.9%) and faster revenue growth (9.1% vs. 7.9%).
P/E vs sector
25.7x
median 25.4x
ROE vs sector
20.8%
median 14.9%
Growth vs sector
9.1%
median 7.9%
Sector rank
#15
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$115.07 – $186.98
vs. $126.49 today · expected CAGR -2% – 8%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $7.57B | $8.25B | $9.00B | $9.81B | $10.69B |
| Net income | $1.44B | $1.57B | $1.71B | $1.86B | $2.03B |
| EPS | $5.09 | $5.55 | $6.05 | $6.60 | $7.19 |
| Share price (low) | $81.52 | $88.85 | $96.85 | $105.57 | $115.07 |
| Share price (high) | $132.46 | $144.39 | $157.38 | $171.55 | $186.98 |
| CAGR (low–high) | -36% / 5% | -16% / 7% | -9% / 8% | -4% / 8% | -2% / 8% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for A:
- High net margins (19.6%) point to pricing power or efficiency.
- Strong return on equity (20.8%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.5x) lowers risk.
- Our model's overall read is Favorable (62/100).
The case against A:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Agilent Technologies is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 25.7x earnings, which our model scores Favorable (62/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.